Small-molecule research chemicals, including SERMs, aromatase inhibitors, PDE5 inhibitors, thyroid hormones, and dopamine agonists.
Third-generation non-steroidal aromatase inhibitor developed by AstraZeneca, studied for estrogen suppression in breast-cancer research.
Long-acting dopamine D2 receptor agonist, studied for suppression of prolactin in endocrine research.
Selective estrogen receptor modulator, studied for stimulation of gonadotropin release in ovulation and fertility research.
Dual 5-alpha-reductase inhibitor developed by GlaxoSmithKline, studied for suppression of dihydrotestosterone in hair-loss and prostate research.
Trans-isomer of clomiphene and a selective estrogen receptor modulator, studied for stimulating endogenous testosterone production.
Steroidal aromatase inhibitor that irreversibly inactivates the aromatase enzyme, studied in estrogen-suppression and breast-cancer research.
Third-generation non-steroidal aromatase inhibitor developed by Novartis, studied in estrogen-suppression and breast-cancer research.
Second-generation selective estrogen receptor modulator developed by Eli Lilly, studied in bone-density and estrogen-signaling research.
Selective estrogen receptor modulator and a longstanding reference compound in breast-cancer and hormonal research.
Selective estrogen receptor modulator developed by Orion Pharma, studied in breast-cancer and hormonal research.
